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Chronic renal diseases as a public health problem: Epidemiol-
ogy, social, and economic implications. The impact of chronic
kidney disease (CKD) on the global burden of diseases is proba-
bly underestimated by current methods of evaluation. However,
CKD are emerging as a major health problem. First, the costs of
renal replacement therapy are excedingly high and are consum-
ing a significant proportion of health care budgets of developed
countries, while in developing countries are out of reach. Sec-
ond, complex interaction are clearly emerging between chronic
kidney, cardiovascular disease, and diabetes.
CHRONIC RENAL DISEASES AS A PUBLIC
HEALTH PROBLEM
Chronic kidney disease (CKD) is a worldwide public
health problem. According to the World Health Report
2002 and Global Burden of Disease (GBD) project, dis-
eases of the kidney and urinary tract contribute to the
global burden of diseases, with approximately 850,000
deaths every year and 15,010,167 disability-adjusted life
years [1–3]. They are the 12th cause of death and the 17th
cause of disability, respectively. The global incidence and
prevalence of CKD, however, may be underestimated by
these data for a number of reasons.
First, in the World Health Report, the item “Disease
of Genitourinary System” is articulated in only 2 spe-
cific cause groups: “Nephrosis and nephritis” and “Be-
nign prostatic hypertrophy,” a classification that does not
provide any significant insight into the contribution of
specific kidney diseases to the global burden of disease.
Second, patients with CKD are at high risk of cardio-
vascular diseases (CVD) and cerebrovascular diseases,
and they are more likely to die of CVD than to de-
velop terminal renal failure. Moreover, patients with
CVD often develop CKD during the course of their dis-
ease. Therefore, an unknown proportion of people whose
death and disability are attributed to CVD have kidney
disease as well.
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Diabetes mellitus is responsible for 895,000 deaths
and 3,412,231 disability-adjusted life years worldwide, ac-
cording to the GBD project. There are currently 170 mil-
lion patients with diabetes: approximately 30% of them
have diabetic nephropathy, and this proportion is even
higher in some ethnic groups. The presence of CKD in-
creases the risk of death of CVD in patients with diabetes.
In summary, the contribution of CKD to the global
burden of disease may be currently underestimated by
numbers provided by the GBD project.
PREVALENCE OF END-STAGE RENAL DISEASE
Renal registries offer an important source of informa-
tion on several aspects of chronic kidney disease (CKD).
They are useful in characterizing the end-stage renal dis-
ease (ESRD) population, describing the prevalence and
incidence of ESRD and trends in mortality and disease
rates, and investigating relationships among patient de-
mographics, treatment modalities, and morbidity. In sum-
mary, renal registries are very useful to gain insight on the
burden of kidney diseases and allow comparisons among
countries [4–6].
Unfortunately, the quality of these national registries
is uneven. For example, some registries are updated
yearly, and data reflect variations of the ESRD popula-
tion almost in real time. Other registries are updated less
promptly. The items covered by questionnaires are not
the same in all registries, and the completeness of data is
not even; in some countries not all dialysis facilities an-
swer to the questionnaire. In summary, renal registries
are a very important tool to measure the capability of
nations to provide renal replacement therapy (RRT) and
also allow international comparisons, even considering
the limitations mentioned previously.
We know much less about the prevalence and incidence
of ESRD in those countries in which a regular national
registry is not available. For some countries, data are pro-
vided by small observational series or rely on reports from
personal experience of kidney physicians, but the quality
of these data is uneven [7].
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A recent global estimate of the global burden of ESRD
was provided by Moeller and colleagues [8]. According
to their survey, which included 122 countries, the approx-
imate total number of patients on RRT is over 1.4 million.
More than 80% of patients on RRT live in Europe, North
America, and Japan.
There is a wide variation in prevalence rate, expressed
as number of patients per million population, among
countries. There is a strong relationship between preva-
lence rate and per capita income, and governmental in-
frastructure, which can influence both the availability and
quality of dialysis and transplantation services.
The prevalence rate of RRT is 644 patients per mil-
lion people in the 15 countries of the European Union
[9], where the average gross income is over US $22,000
per capita, as compared with a prevalence rate of 166
patients per million population in Central and Eastern
European countries, where the average per capita income
is US $4480 [10].
If we take more extreme examples, the dependence of
availability of dialysis is even more striking. Prevalence
rate of ESRD is 582 patients per million people in Fin-
land, which had an average income of US $25,130 in the
year 2000, and as low as 52 patients per million people in
Bangladesh, where the average income is only US $370
per capita [6].
Treatment of ESRD is a low priority for cash-strapped
public hospitals and in the absence of health insurance
plans. In India and Pakistan, less than 10% of all pa-
tients receive any kind of RRT [11]. The vast majority
of patients starting hemodialysis dies or stops treatment
because of cost constraints within the first 3 months. Al-
though renal transplantation is the cheapest option, only
about 5% of all patients with ESRD have a transplant.
ESTIMATED PREVALENCE OF KIDNEY
DYSFUNCTION
Renal registries record data of patients who are at the
last stage of kidney disease. Much less is known about
the prevalence of earlier stages of CKD, when symptoms
may be mild or neglected by patients or their caring physi-
cians. Indeed, it has been acknowledged that the majority
of individuals at early stage of CKD have gone undiag-
nosed and undertreated. Poor standardization of CKD
definition has hampered the assessment of the burden of
CKD even in high-income countries. Late detection of
CKD is a lost opportunity for application of therapeutic
measures shown to retard progression of CKD.
An estimate of the prevalence of CKD in a high-income
country has been provided by the Third National Health
and Nutrition Examination Survey. The survey was con-
ducted from 1988 to 1994 by the National Center for
Health Statistics of the Centers for Disease Control in the
United States [12]. A sample of 15,625 noninstitutional-
ized individuals aged 20 years and older was analyzed.
The estimated prevalence of CKD is 11% of the adult
population in the United States (19.2 million). By stage,
an estimated 5.9 million have stage 1 CKD (persis-
tent albuminuria with normal glomerular filtration rate),
whereas the remaining 13 million have variable degrees
of kidney dysfunction, from mild to severe functional im-
pairment. A sizeable proportion of these patients will
eventually progress toward ESRD and will require RRT.
Early detection of CKD is therefore important for imple-
menting all available measures that are known to retard
or arrest loss of renal function, and also for forecasting
the need of dialysis in a given region or country.
GLOBAL PERSPECTIVES IN RRT
Although there is a lack of uniform data around the
world, the total number of those who need RRT is grow-
ing in all high-income countries and also in upper middle-
income countries.
In the United States in 2003, 360,000 people with
ESRD were on RRT. There were 150,000 10 years ago,
and according to a recent forecast analysis there will be
650,000 10 years from now. The forecasted point preva-
lence of total ESRD counts had an exponential growth
trend, whereas the forecasted incident counts demon-
strated a more linear trend [13]. This different pattern of
growth is probably attributable to improved survival rates
for dialysis and transplantation: death rates are lower and
patients are accumulated at a rate that exceeds reduced
influx of new patients.
Growth in the ESRD population has relevant implica-
tions for health care systems. The 1-year cost per patient
on maintenance hemodialysis is more than US $52,000,
and the cost for transplantation is approximately US
$18,500 [6]. In the United States, the expenditure of Medi-
care for dialysis is 5% of total budget but serves only 0.7%
of patients assisted by Medicare [6]. In Europe, the pro-
portion of the total health care budget absorbed by RRT
varied in 1994 from 0.7% in the United Kingdom to 1.8%
in Belgium, whereas the population with ESRD is only
0.022% to 0.04%, respectively, of the total population
[14].
Although there are not similar studies in other coun-
tries, it is likely that in all high-income countries, the num-
ber of people requiring RRT will grow at a similar rate
during the next decade.
It is interesting to examine the changing pattern of
ESRD in Central and Eastern Europe [10]. Data col-
lected from 15 Central and Eastern European countries
documented an expansion of renal replacement in this re-
gion during the last decade. When these countries were
associated with the former Soviet Union, the availabil-
ity of RRT was very poor. From 1990 to 1996, a period
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that followed profound socioeconomic changes in Cen-
tral and East Europe from 1989, the number of hemodial-
ysis centers increased by 56% and the number of centers
performing peritoneal dialysis increased by 296%. The
number of patients increased by 78% (hemodialysis) and
306% (peritoneal dialysis), respectively. Still, the total
number of patients on dialysis (prevalence) and the num-
ber of those who initiate every year (incidence) are still
different in the European Union and Central and Eastern
Europe [9]. Such a great difference clearly underlines that
socioeconomic status is the major determinant of avail-
ability of RRT.
Data for many of the low-income countries are not
available, but given the prevalence of poor socioeco-
nomic factors, the incidence of ESRD is likely to be
greater than in high-income countries. In poor nations,
for example in sub-Saharan Africa, economic and man-
power factors dictate a conservative approach to therapy
in most instances, but the majority of those with ESRD
perish because of lack of funds; very few can afford reg-
ular maintenance dialysis and renal transplantation is of-
ten not available [15]. Limitations to regular maintenance
dialysis include the paucity of dialysis units, restriction of
those units to urban centers, and absence of government
funding or subsidy and health insurance to cover high
costs of dialysis. The few available units are plagued with
multiple problems: old machines frequently break down,
and there is an absence of adequate maintenance, tech-
nical support, and spare parts, and lack of consumables
and frequent power outages.
In India and Pakistan, treatment of ESRD is a low
priority for cash-strapped public hospitals, and in the ab-
sence of health insurance plans, or private insurance, less
than 10% of all patients receive any kind of RRT [11].
The vast majority of patients starting hemodialysis dies
or stops treatment because of cost constraints within the
first 3 months, and less than 2% of patients are started
on ambulatory peritoneal dialysis. Although renal trans-
plantation is the cheapest option, only about 5% of all
patients with ESRD end up having a transplant.
In summary, the incidence of ESRD is increasing
worldwide at an annual growth rate of 8%, far in excess
of the population growth rate of 1.3%. Nearly 1 million
people or only 15% of the world population are receiv-
ing hemodialysis worldwide, 80% of whom are treated in
Europe, North America, and Japan. Twenty percent are
treated in 100 developing countries that make up over
50% of world population, and a sizeable proportion of
people living in the poorest countries dies of uremia be-
cause of the complete lack of RRT.
MODALITY OF RRT
Modality of RRT varies widely around the world,
and differences depend mostly on health care systems.
Hemodialysis is the most used modality of RRT, with a
utilization rate that ranges from 40% of prevalent pa-
tients in Australia to 95% in Japan. The use of peritoneal
dialysis is very low in Japan (only 5% of patients on preva-
lent dialysis) and very high in New Zealand (58.7%). In
most countries, the percentage of patients on peritoneal
dialysis ranges from 10% to 25% [6].
The use of kidney transplants also differs widely
around the world. In 7 European countries and in North
America, transplant prevalence rates are greater than
30 per million population [6]. The rate of functioning
grafts is also very high in Europe and North America and
is increasing over time, which indicates that there is an
improvement in graft survival. There is also a growing at-
titude to perform transplantations in older patients. How-
ever, efforts to expand transplant programs are limited by
organ availability, a problem that exists in all developed
countries.
In low-income countries, the use of transplant as
a modality of RRT is not widely available [16]. In
Bangladesh, the prevalence rate of functioning graft is
only 2.6 per million population. In India and Pakistan,
only about 5% of all patients with ESRD receive a kidney
transplant [11]. Living related donor transplants consti-
tute 30% to 40% of all transplants in India, but there is
a conspicuous gender bias with female donors donating
kidneys to their male relatives. Cadaveric transplantation
has yet to increase and accounts for less than 2% of all
transplants. The enactment of legislation to regulate re-
nal transplantation in India has not been able to prevent
unrelated (paid) donor transplants, which constitute 60%
to 70% of all renal transplants.
In North Africa (Egypt, Libya, Tunisia, Algeria,
Morocco), renal transplantation, largely from live (often
unrelated) donors, is offered to less than 5% of patients
with ESRD [17].
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